Saturday 17 October 2026
Export ITRMF’s income statement to Excel — free account
Iterum Therapeutics PLC
ITRMF Healthcare Biotechnology
In the quarter to September 2025, revenue grew 110.8%, EPS grew 33.3% and free cash flow fell 179.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.00
0.00
NaN
Follow ITRMF
Iterum Therapeutics PLC (ITRMF) P/E ratio
Iterum Therapeutics PLC has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 17.9× (April 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2025 | 0.0× | — |
| Mar 2019 | 0.0× | — |
| Dec 2018 | 0.0× | — |
| Sep 2018 | 0.0× | — |
| 3 more quarters | Free account |
Against its own ten years
Low 0.0×
High 17.9×
Ten-year median
0.0×
Current reading's percentile
97
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NEXI NexImmune, Inc. compare | n/m |
| SILO Silo Pharma, Inc. compare | n/m |
| ARTL Artelo Biosciences, Inc. compare | n/m |
| CARM Carisma Therapeutics Inc. compare | n/m |
| MLEC Moolec Science SA compare | n/m |
| TRVN Trevena, Inc. compare | n/m |
| ITRMF Iterum Therapeutics PLC | n/m |
| GNPX GENPREX compare | 0.0× |
| ABPO Abpro Holdings Inc. compare | 0.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)